Polar Asset Management Partners Inc. Makes New Investment in Compass Pathways PLC Sponsored ADR $CMPS

Polar Asset Management Partners Inc. acquired a new stake in Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 75,000 shares of the company’s stock, valued at approximately $415,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Persistent Asset Partners Ltd purchased a new stake in shares of Compass Pathways during the 4th quarter worth $38,000. Parallel Advisors LLC increased its holdings in Compass Pathways by 8,450.6% in the first quarter. Parallel Advisors LLC now owns 7,268 shares of the company’s stock valued at $40,000 after buying an additional 7,183 shares during the last quarter. Advisory Services Network LLC purchased a new position in Compass Pathways in the third quarter valued at $41,000. North Star Investment Management Corp. raised its stake in Compass Pathways by 1,354.0% in the first quarter. North Star Investment Management Corp. now owns 7,517 shares of the company’s stock valued at $42,000 after buying an additional 7,000 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in Compass Pathways in the fourth quarter valued at $47,000. 46.19% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. Compass Point set a $25.00 price objective on Compass Pathways in a research report on Tuesday, July 7th. Wolfe Research reissued an “outperform” rating on shares of Compass Pathways in a research report on Tuesday, July 7th. Evercore upgraded Compass Pathways from an “in-line” rating to an “outperform” rating and set a $21.00 target price for the company in a research note on Wednesday, July 8th. Canaccord Genuity Group upped their price target on Compass Pathways from $18.00 to $20.00 and gave the company a “buy” rating in a report on Friday, June 26th. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $17.00 price target on shares of Compass Pathways in a report on Tuesday, July 7th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $23.36.

Compass Pathways Stock Performance

Shares of CMPS stock opened at $11.27 on Tuesday. The stock has a market capitalization of $1.52 billion, a PE ratio of -3.58 and a beta of 2.47. The company has a quick ratio of 3.32, a current ratio of 3.32 and a debt-to-equity ratio of 0.15. Compass Pathways PLC Sponsored ADR has a 52-week low of $3.92 and a 52-week high of $15.40. The stock’s 50-day moving average price is $12.52 and its 200 day moving average price is $9.06.

Compass Pathways (NASDAQ:CMPS) last issued its earnings results on Wednesday, May 13th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.15. As a group, equities research analysts forecast that Compass Pathways PLC Sponsored ADR will post -1.24 EPS for the current year.

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.